CAR-T Meeting 2022 | An update on the EBMT-EHA GoCART initiative
Jürgen Kuball, MD, PhD, Utrecht University, Utrecht, Netherlands, outlines the activity and progress of the EBMT-EHA GoCART initiative, which aims to enhance the potential of chimeric antigen receptor T-cell (CAR-T) therapies by harmonizing the data collected from CAR-T patients across Europe and engaging with different stakeholders to obtain joint accreditations for CAR-Ts that will be produced in their centers. Prof. Kuball also shares his excitement about the scientific projects supported by the GoCART initiative. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Disclosures
JK is co-founder and shareholder of Gadeta and holds patents on different types of engineered immune cells and immune cell selection licensed to different commercial partners and receives revenues. JK received research support from Gadeta, Novartis, Miltenyi Biotech. For more details please visit https://www.umcutrecht.nl/en/research/researchers/kuball-jhe .
